Literature DB >> 2990488

Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage.

T Rowe, G Kupfer, W Ross.   

Abstract

This laboratory and others previously proposed that the antitumor effects of the epipodophyllotoxin compounds are based on their abilities to stimulate DNA cleavage by a DNA topoisomerase. To explore this relationship further, we studied the intercalating agent ethidium bromide and found that it blocked epipodophyllotoxin-induced DNA cleavage by DNA topoisomerase II in vitro as well as in vivo. Using an in vitro assay consisting of purified calf thymus DNA topoisomerase II, end-labeled DNA, and the epipodophyllotoxin teniposide, we found that ethidium bromide markedly interfered with the enzyme-mediated DNA cleavage. Furthermore, ethidium bromide also blocked the formation of DNA single- and double-strand breaks in mouse L1210 cells when exposed to the epipodophyllotoxin etoposide. This effect cannot be explained by alterations in drug accumulation since steady-state drug concentrations were unchanged, and the effect was also observed in isolated nuclei. In addition to its effects on epipodophyllotoxin-mediated DNA breakage, ethidium bromide also potently inhibited the cytotoxic effects of etoposide but only when present during drug treatment. Thus, we believe that ethidium bromide may be a useful tool to investigate drug-induced perturbations of topoisomerase activity and their relationship to antitumor effect. Our data strongly support the hypothesis that the antitumor activity of epipodophyllotoxins is based on the ability to stimulate the formation of a cleavable complex between DNA topoisomerase and DNA.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2990488     DOI: 10.1016/0006-2952(85)90530-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

1.  Etoposide-induced DNA cleavage in human leukemia cells.

Authors:  C M Edwards; B S Glisson; C K King; S Smallwood-Kentro; W E Ross
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Characterization of an etoposide-resistant human small-cell lung cancer cell line.

Authors:  K Minato; F Kanzawa; K Nishio; K Nakagawa; Y Fujiwara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 3.  Topoisomerases, new targets in cancer chemotherapy.

Authors:  J G Zijlstra; S de Jong; E G de Vries; N H Mulder
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

Review 4.  Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.

Authors:  J J Holthuis
Journal:  Pharm Weekbl Sci       Date:  1988-06-17

5.  DNA damage response to the Mdm2 inhibitor nutlin-3.

Authors:  Rajeev Verma; Marc J Rigatti; Glenn S Belinsky; Cassandra A Godman; Charles Giardina
Journal:  Biochem Pharmacol       Date:  2010-02-15       Impact factor: 5.858

6.  The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.

Authors:  Brian B Hasinoff; Xing Wu; John L Nitiss; Ragu Kanagasabai; Jack C Yalowich
Journal:  Biochem Pharmacol       Date:  2012-10-05       Impact factor: 5.858

7.  Antitumor agents. 125. New 4 beta-benzoylamino derivatives of 4'-O-demethyl-4-desoxypodophyllotoxin and 4 beta-benzoyl derivatives of 4'-O-demethylpodophyllotoxin as potent inhibitors of human DNA topoisomerase II.

Authors:  X M Zhou; Z Q Wang; H X Chen; Y C Cheng; K H Lee
Journal:  Pharm Res       Date:  1993-02       Impact factor: 4.200

Review 8.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

9.  Selective inhibition of topoisomerases from Pneumocystis carinii compared with that of topoisomerases from mammalian cells.

Authors:  C C Dykstra; D R McClernon; L P Elwell; R R Tidwell
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

10.  Characterization of an etoposide-resistant human ovarian cancer cell line.

Authors:  N Kubota; K Nishio; Y Takeda; T Ohmori; Y Funayama; H Ogasawara; T Ohira; H Kunikane; Y Terashima; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.